Evotech (EVO) Q4 2025: Just Biologics Grows 40%, Reshapes Margin Profile for 2026
Evotech’s strategic shift toward technology-enabled biologics and operational streamlining is redefining its profit engine and future growth levers. The company’s Horizon transformation has begun to deliver structural cost savings, while the Just Evotech Biologics segment’s non-Sandoz, non-DOW business doubled its share within the segment over two years. Investors should watch for margin expansion and deal flow as the pipeline matures and cost actions take hold in 2026’s second half.
Summary
- Biologics Model Shift: Technology-driven Just Biologics now drives growth and margin expansion.
- Operational Overhaul: Horizon restructuring targets 75 million euro in annual savings by 2027.
- Pipeline Milestones: Asset maturation and equity monetization set up further upside beyond 2026.
Performance Analysis
Evotech’s 2025 results reflect a business in strategic transition, with group revenues at the high end of guidance but segment divergence sharpening. The Just Evotech Biologics (JAB) segment delivered 39.8% full-year revenue growth, driven by the Sandoz agreement and robust non-Sandoz, non-DOW customer expansion, which now accounts for 30% of JAB revenues (up from 25% in 2024) and is set to reach 50% in 2026. This segment’s shift to an asset-light, technology enablement model is materially lifting margins and recurring revenue quality.
Conversely, the Discovery and Preclinical Development (DMPD) segment continued to face headwinds, with revenues down 13.5% for the year, reflecting market softness and overcapacity. Adjusted EBITDA for DMPD turned negative, underscoring the need for the Horizon transformation, which is already underway with site closures and workforce reductions.
- Margin Upside from Mix Shift: JAB’s high-margin model and Sandoz royalties will increasingly dominate group profitability.
- Cost Discipline Delivers: 60 million euro in annualized cost savings and 38% CapEx reduction support liquidity and flexibility.
- Equity Monetization Windfall: Strategic divestments (e.g., Tubulus, Dark Blue) generated over 110 million euro in cash, with further upside possible from remaining stakes.
Liquidity remains robust (476 million euro in cash, net cash position), providing a buffer as the company navigates a challenging first half of 2026 and positions for recovery in the back half. The company’s ability to maintain R&D investment while reducing spend as a percent of revenue signals disciplined capital allocation amid volatility.
Executive Commentary
"2025 was a year of significant progress for Evotech as we laid critical groundwork for the company's next chapter of sustainable and profitable growth. Our four levers of mid-term value creation, scientific leadership, operational excellence, better monetization of just Evotech biologics, and capturing pipeline value have already translated strategy into targeted action."
Christian Wojciechowski, Chief Executive Officer
"Adjusted group EBITDA increased by 29.5 million euros or 103.6% to 58 million euros in the fourth quarter and by 18.5 million euros or 81.9% to 41.1 million euros for the full year of 2025 compared to the same period in 24. The improvement in our cash liquidity reflects disciplined financial execution, including the monetization of technology leadership through just Evotech biologics, the realization from maturing equity stakes, and our continued shift toward a capital efficient operating model."
Paul Hitchen, Chief Financial Officer
Strategic Positioning
1. Biologics as the New Growth Engine
Just Evotech Biologics (JAB), continuous manufacturing and partner enablement, is now the primary driver of group growth and future margin expansion. The Sandoz agreement (valued at $650 million plus royalties) and rapid expansion of non-Sandoz, non-DOW customers validate the pivot away from capacity-constrained manufacturing. The business is positioned for durable, high-margin, technology-led revenue streams, with royalty contributions expected post-2028 as biosimilars reach market.
2. Horizon Transformation Reshapes Cost Structure
Horizon, Evotech’s operating model overhaul, targets 75 million euro in run-rate savings by 2027 through site consolidation (from 14 to 10), 800 headcount reductions, and SG&A streamlining. The transformation is phased, with 20-30% of savings expected to materialize in 2026 and the majority in 2027. Management emphasizes careful execution to avoid customer disruption, with no negative feedback reported from partners.
3. Portfolio Monetization and Pipeline Evolution
Evotech’s equity portfolio, early-stage biotech investments, is transitioning from operational involvement to value realization. Recent exits (Tubulus, Dark Blue Therapeutics) delivered over 110 million euro in cash, with contingent milestone upside exceeding 150 million euro. The pipeline’s maturation (two assets in phase two, five in phase one) promises future milestone and royalty inflows, particularly as BMS collaborations move toward clinical-stage economics.
4. Commercial Organization Rebuild
Appointment of a new Chief Commercial Officer with AI and pharma deal experience signals a focus on integrated, technology-driven sales and partner engagement. Leading indicators (proposal volume up 50%, improved turnaround times) support management’s view that the commercial transformation is gaining traction, setting up a stronger deal pipeline for the second half of 2026 and beyond.
5. Margin Expansion Anchored in Mix and Productivity
By 2028, Evotech targets a 20% adjusted EBITDA margin (from current low single digits), driven by higher-margin biologics, operational leverage, and automation. The company expects margin progression to accelerate as cost savings phase in and as late-stage pipeline assets generate milestones and royalties, smoothing out historical volatility tied to project-based revenue.
Key Considerations
Evotech’s 2025 was a year of foundational change, with the business model, cost structure, and commercial approach all undergoing significant evolution. The strategic context now hinges on execution through 2026’s transition year and the realization of pipeline and portfolio value.
Key Considerations:
- Biologics Revenue Mix Shift: Non-Sandoz, non-DOW business in JAB will reach 50% of segment revenue in 2026, up from 30% in 2025, doubling in two years and supporting recurring, high-margin growth.
- Horizon Cost Savings Timetable: 20-30% of targeted 75 million euro in annual savings expected in 2026, with full effect by end of 2027, driving margin expansion and cash flow improvement.
- Pipeline Monetization: Equity divestments generated >110 million euro in cash, with further upside from 29 remaining portfolio companies and contingent milestone payments.
- Commercial Execution Risk: Early signs of proposal and order recovery in DMPD segment, but sustained deal flow is required to offset ongoing market softness and overcapacity.
- Segment Divergence: DMPD remains a drag on profitability, but is expected to stabilize with single-digit growth in H2 2026; JAB’s margin profile will increasingly dominate group results.
Risks
Execution risk remains high as Evotech navigates site closures, workforce reductions, and a commercial organization rebuild. The DMPD segment’s recovery is not yet assured and depends on sustained improvement in biotech funding and deal flow. Foreign exchange headwinds (3.5% impact in 2026) and the non-recurrence of large license payments (Sandoz) will create YoY revenue noise. Finally, pipeline monetization is inherently lumpy and contingent on external buyer interest and clinical progression.
Forward Outlook
For 2026, Evotech guided to:
- Group revenues of 700 to 780 million euro (reported FX), 730 to 810 million euro (constant FX)
- Adjusted group EBITDA of 0 to 40 million euro (reported FX), 10 to 50 million euro (constant FX)
For full-year 2026, management maintained a transition-year outlook:
- First half expected to remain soft, with recovery and incremental partnerships in the second half
- Non-Sandoz, non-DOW JAB revenues to grow 40% YoY, offsetting DOW declines
Management highlighted that operational savings and new deal flow will become more visible in H2 2026, and that margin expansion is expected to accelerate into 2027 as Horizon measures phase in.
Takeaways
Evotech’s transformation is entering its execution phase, with the biologics segment’s technology-driven model now the clear profit anchor. Margin expansion and cash generation depend on the Horizon program’s timely delivery and commercial traction in the DMPD segment.
- Biologics Margin Leverage: JAB’s asset-light, technology enablement model is redefining group profitability, with royalty streams to follow from 2028 onward.
- Cost Actions Support Resilience: Horizon’s 75 million euro savings target and site consolidation will structurally lower the cost base and improve operating leverage.
- Pipeline and Portfolio Upside: Asset maturation and equity monetization provide optionality, but timing and magnitude remain difficult to forecast.
Conclusion
Evotech’s 2025 results mark a decisive pivot toward a technology-enabled, capital-efficient growth model anchored by biologics and operational excellence. While near-term headwinds persist, the company’s structural actions and pipeline maturation offer a credible path to margin expansion and long-term value creation.
Industry Read-Through
Evotech’s shift toward high-margin, technology-enabled biologics and partner enablement signals a broader trend among contract research and manufacturing organizations to prioritize recurring, asset-light revenue streams over traditional capacity-based models. The company’s experience with Horizon restructuring and equity monetization offers a template for peers grappling with market volatility and overcapacity. The accelerating integration of AI in drug discovery, as referenced by management, also reflects a sector-wide push for productivity and differentiated platform value. Investors in the CRO and biotech tools space should monitor margin mix, cost discipline, and the ability to monetize pipeline and equity assets as key differentiators in the coming cycle.